Article thumbnail

Visceral Leishmaniasis and Arsenic: An Ancient Poison Contributing to Antimonial Treatment Failure in the Indian Subcontinent?

By Meghan R. Perry, Susan Wyllie, Vijay Kumar Prajapati, Joerg Feldmann, Shyam Sundar, Marleen Boelaert and Alan H. Fairlamb
Topics: Viewpoints
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3181240
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2005). 51Sb antimony
  2. (2000). Amplification of the ABC transporter gene PGPA and increased trypanothione levels in potassium antimonyl tartrate (SbIII) resistant Leishmania tarentolae.M o l Biochem Parasitol
  3. (1996). An ATP-dependent As(III)-glutathione transport system in membrane vesicles of Leishmania tarentolae.
  4. (2007). Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome?
  5. (2003). Antimony uptake systems in the protozoan parasite Leishmania and accumulation differences in antimony-resistant parasites.
  6. (2010). Arsenic exposure from drinking water, and all-cause and chronicdisease mortalities in Bangladesh (HEALS): a prospective cohort study.
  7. (2003). Arsenic groundwater contamination in MiddleGanga Plain,Bihar,India:a futuredanger? Environ Health Perspect
  8. (2009). Arsenic in drinking water and adult mortality a population-based cohort study in rural Bangladesh.
  9. (2009). Arsenic pollution: a global synthesis.
  10. (2005). Arsenic speciation in hair extracts.
  11. (1988). Did medicated salt hasten the spread of chloroquine resistance in Plasmodium falciparum.
  12. (2001). Drug resistance in Indian visceral leishmaniasis.
  13. (2006). Drug resistance in Leishmaniasis.
  14. (2004). Drug uptake and pharmacological modulation of drug sensitivity in leukemia by AQP9.
  15. (2004). Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani.
  16. (2005). Effect of chronic intake of arsenic-contaminated water on liver.
  17. (2010). Elevated levels of tryparedoxin peroxidase in antimony unresponsive Leishmania donovani field isolates.
  18. (1984). Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis).
  19. (1999). Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimonyresistant strains of Leishmania donovani.
  20. (2010). Groundwater quality in shallow aquifers of India.
  21. (1994). High level arsenite resistance in Leishmania tarentolae is mediated by an active extrusion system.
  22. (2008). Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal—the challenges for diagnosis and treatment.
  23. (2005). Implications of oxidative stress and hepatic cytokine (TNF-alpha and IL-6) response in the pathogenesis of hepatic collagenesis in chronic arsenic toxicity.
  24. (2010). In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent.
  25. (1987). Leishmania mexicana uptake of sodium stibogluconate (pentostam) and pentamidine by parasite and macrophages.
  26. (2010). Linking in vitro and in vivo survival of clinical Leishmania donovani strains.
  27. (1999). Methylation of inorganic arsenic in different mammalian species and population groups.
  28. (2002). Microbial arsenic: from geocycles to genes and enzymes.
  29. (2007). Molecular mechanisms of antimony resistance in Leishmania.
  30. (2004). Ranjan A
  31. (1988). Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomised study.
  32. (2005). Role of the ABC transporter MRPA (PGPA) in antimony resistance in Leishmania infantum axenic and intracellular amastigotes.
  33. (2008). Roles of trypanothione S-transferase and tryparedoxin peroxidase in resistance to antimonials.
  34. S h a n k a rR ,B o e l a e r tM ,S u n d a rS(
  35. (2006). The epidemiology of visceral leishmaniasis in Bangladesh: prospects for improved control.
  36. (2001). The Leishmania ATP-binding cassette protein PGPA is an intracellular metal-thiol transporter ATPase.
  37. (2006). The role of migration and remittances in promoting livelihoods in Bihar. London: Overseas Development Institute.
  38. (1981). The treatment of Kala-Azar -new approaches to an old problem.
  39. (2010). Transmission dynamics and underreporting of Kala-azar in the Indian state of Bihar.
  40. (2003). Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline.
  41. (2005). Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India,
  42. (2006). Visceral leishmaniasis (kala-azar): challenges ahead.
  43. (2009). Visceral leishmaniasis elimination programme in India, Bangladesh, and Nepal: reshaping the case finding/case management strategy. PLoS Negl Trop Dis 3:
  44. (2002). Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda.